ArticleEJHaem2023

A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

Mayur Narkhede et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.